Gland Pharma launches Bortezomib for injection in US market

04 May 2022 Evaluate

Gland Pharma through its partner has launched Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial in the US Market. It is the bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial of Takeda Pharmaceuticals U.S.A., Inc. Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.

Velcade has a market size of USD 1,172 million for the twelve months ending March 2022, according to IQVIA. Gland Pharma’s partner has received the ANDA approval for the product from U.S. Food & Drug Administration (USFDA). Gland Pharma is manufacturing and supplying this product to its partner for the US market.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1681.95 -39.70 (-2.31%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×